As previously reported, Guggenheim initiated coverage of Pharvaris (PHVS) with a Buy rating and $32 price target telling investors that the company is positioned to address both the on-demand and prophylaxis segments of the hereditary angioedema market with once a day, oral medicines. Deucrictibant IR could become a $400M medicine, says the analyst, who sees a “very high chance” of a positive readout in Pharvaris’ RAPIDe-3 Phase 3 trial.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHVS:
- Pharvaris initiated with a Buy at Guggenheim
- Pharvaris Announces 2025 Annual Shareholders Meeting Amidst Phase 3 Trials
- Pharvaris’s Deucrictibant: Expanding Market Reach in Bradykinin-Mediated Angioedemas with Promising Phase 3 Trials
- Pharvaris’s Strategic Advancements and Clinical Progress Justify Buy Rating
- Pharvaris presents data supporting ongoing clinical development of deucrictibant